Forbes·Jun 17, 2026
The Healthcare M&A WaveIn this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Editas Medicine, Inc.(EDIT)Earnings, Financials & Key Ratios
EDIT•NASDAQ
$3.65
Price updated Jul 6, 2026
AboutEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Show more
- Revenue$41M+25.4%
- EBITDA-$94M+61.7%
- Net Income-$160M+32.5%
- EPS (Diluted)-1.80+37.5%
- Gross Margin100%
- EBITDA Margin-232.13%+69.4%
- Operating Margin-245.15%+68.5%
- Net Margin-395.01%+46.2%
- ROE-198.14%-102.0%
EDIT Price & Volume
Editas Medicine, Inc. (EDIT) stock price & volume — 10-year historical chart
Loading chart...
Clinical Milestone Dependence Drives Severe Capital Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical binary outcome dependency
Key Thesis Takeaways
- Editas Medicine faces a precarious financial outlook characterized by extreme revenue volatility and the rapid depletion of its equity base, which has fallen to $4.4 million as of 2026Q1.
- The company's reliance on intermittent milestone payments rather than a sustainable commercial model leaves it highly vulnerable to clinical binary outcomes for its EDIT-301 program.
- Investors should monitor the company's narrowing liquidity runway and the significant escalation in debt-to-equity ratios, which reached 16.33 in the most recent quarter, as these factors suggest a high probability of future dilutive financing.
Verdict Logic
the company's accumulated deficit of $1.7 billion and the rapid erosion of its asset base from $499.2 million to $149.3 million since 2023Q4 indicate severe long-term sustainability risks.
EDIT Growth Metrics
Editas Medicine, Inc. (EDIT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years37.9%
5 Years-14.89%
3 Years27.15%
TTM7.97%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.61%
Return on Capital
10 Years-43%
5 Years-46.85%
3 Years-52.95%
Last Year-49.1%
EDIT Recent Earnings
Editas Medicine, Inc. (EDIT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.26+13.3%
$0.30
Rev
$3M-55.6%
$6M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.06+77.8%
$0.27
Rev
$25M+196.3%
$8M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.28+26.3%
$0.38
Rev
$8M-10.8%
$8M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.63-53.7%
$0.41
Rev
$4M+97.0%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.26vs $0.30+13.3% | $3Mvs $6M-55.6% |
| Q2 2026 | Mar 9, 2026 | $0.06vs $0.27+77.8% | $25Mvs $8M+196.3% |
| Q4 2025 | Nov 10, 2025 | $0.28vs $0.38+26.3% | $8Mvs $8M-10.8% |
| Q3 2025 | Aug 12, 2025 | $0.63vs $0.41-53.7% | $4Mvs $2M+97.0% |
Based on last 12 quarters of dataView full earnings history →
Latest EDIT News
Recent stock market news and headlines for Editas Medicine, Inc. (EDIT)
Peers Comparison
Key metrics vs top competitors for Editas Medicine, Inc. (EDIT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.65 | $357.36M | -2.03 | 25.39% | -395.01% | -198.14% | — | |
| $61.89 | $5.97B | -9.57 | -89.97% | -13856.54% | -30.88% | — | |
| $35.32 | $3.63B | -43.60 | 120.01% | -49.17% | -5.89% | — | |
| $17.84 | $2B | -4.68 | 16.92% | -597.04% | -57.27% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — | |
| $3.99 | $435.68M | -1.99 | — | — | -70.79% | — |
Compare EDIT vs Peers
Editas Medicine, Inc. (EDIT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EDIT SEC Filings & Documents
Editas Medicine, Inc. (EDIT) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 7, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when EDIT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EDIT Frequently Asked Questions
Editas Medicine, Inc. (EDIT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Editas Medicine, Inc.'s revenue?
Editas Medicine, Inc. (EDIT) reported $38.7M in revenue for fiscal year 2025.
How fast is Editas Medicine, Inc. growing?
Editas Medicine, Inc. (EDIT) grew revenue by 25.4% over the past year. This is strong growth.
Is EDIT profitable?
Editas Medicine, Inc. (EDIT) reported a net loss of $109.0M for fiscal year 2025.
Dividend & Returns
What is EDIT's return on equity?
Editas Medicine, Inc. (EDIT) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
What is Editas Medicine, Inc.'s free cash flow?
Editas Medicine, Inc. (EDIT) had negative free cash flow of $141.1M in fiscal year 2025, likely due to heavy capital investments.